Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pulmonary Disease, Chronic Obstructive 1Pneumonia 1Lung Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Oncolytic Virotherapy 4Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3Tobacco Use Cessation Devices 2Positron-Emission Tomography 2perflutren 1pembrolizumab 1osimertinib 1icotinib 1gallium 68 PSMA-11 1dapagliflozin 1dacomitinib 1clevudine 1aldesleukin 1Vitamin A 1Tomography, Emission-Computed, Single-Photon 1Tetrahydrouridine 1Technetium 1Sulfur Hexafluoride 1Sufentanil 1Standard of Care 1Specimen Handling 1Ropivacaine 1Radiotherapy 1Radiosurgery 1Probiotics 1Practice Guidelines as Topic 1Positron Emission Tomography Computed Tomography 1Pentetic Acid 1Nicotine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Lung Neoplasms × CIMAvax EGF × Clear all
NCT04298606 2026-03-17

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Completed
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pneumonia, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡